Fibroblast Growth Factor-21 as a Therapeutic Agent for Metabolic Diseases

@article{Kharitonenkov2008FibroblastGF,
  title={Fibroblast Growth Factor-21 as a Therapeutic Agent for Metabolic Diseases},
  author={Dr Alexei Kharitonenkov and Armen B. Shanafelt},
  journal={BioDrugs},
  year={2008},
  volume={22},
  pages={37-44}
}
Fibroblast growth factor (FGF)-21 is a unique member of the FGF family, with several molecular characteristics that differ from classical FGFs and exhibiting a pharmacologic profile that includes a variety of metabolic responses in vitro and when tested in vivo in animal models. FGF21 represents a novel and attractive therapeutic agent for type 2 diabetes mellitus, because of its ability to modulate disease phenotype in preclinical settings without inducing any apparent adverse effects… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 50 CITATIONS, ESTIMATED 44% COVERAGE

Therapeutic Role of Fibroblast Growth Factor 21 (FGF21) in the Amelioration of Chronic Diseases

  • International Journal of Peptide Research and Therapeutics
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

FILTER CITATIONS BY YEAR

2008
2019

CITATION STATISTICS

  • 2 Highly Influenced Citations

References

Publications referenced by this paper.
SHOWING 1-10 OF 42 REFERENCES

Cellular signalling by fibroblast growth regulated kinase 1 / 2 and Akt signaling pathways

VP Eswarakumar, I Lax, J Schlessinger
  • Diabetes
  • 2006